DÄ internationalArchiveReferences
References

Original article

A Survey of German Physicians in Private Practice About Contacts With Pharmaceutical Sales Representatives

Dtsch Arztebl Int 2010; 107(22): 392-8; DOI: 10.3238/arztebl.2010.0392

Lieb, K; Brandtönies, S

1. Merten M, Rabbata S: Selbsthilfe und Pharmaindustrie: Nicht mit und nicht ohne einander. Dtsch Arztebl 2007; 104 (46): A 3157–62. VOLLTEXT
2. Korzilius H, Rieser S: Pharmaberater: Für manche Fachmann, für andere Buhmann. Dtsch Arztebl 2007; 104 (4): A 156–61. VOLLTEXT
3. Fugh-Berman A, Ahari S: Following the script: how drug reps make friends and influence doctors. PLoS Med 2007; 4 (4): e150. MEDLINE
4. Steinman MA, Harper GM, Chren MM, Landefeld CS, Bero LA: Characteristics and impact of drug detailing for gabapentin. PLoS Med 2007; 4 (4): e134. MEDLINE
5. Shaughnessy AF, Slawson DC, Bennett JH: Separating the wheat from the chaff: identifying fallacies in pharmaceutical promotion. J Gen Intern Med 1994; 9: 563–8. MEDLINE
6. Gagnon MA, Lexchin J: The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med 2008; 5: 29–33. MEDLINE
7. Campbell EG, Gruen RL, Mountford J, Miller LG, Cleary PD, Blumenthal D: A national survey of physician-industry relationships. N Eng J Med 2007; 356: 1742–50. MEDLINE
8. Segovis CM, Mueller PS, Rethlefsen ML, et al.: If you feed them, they will come: a prospective study of the effects of complimentary food on attendance and physician attitudes at medical grand rounds at an academic medical center. BMC Med Educ 2007; 7: 22–7. MEDLINE
9. Spurling G, Mansfield P: General practitioners and pharmaceutical sales representatives: quality improvement research. Qual Saf Health Care 2007; 16: 266–70. MEDLINE
10. Steinman M, Shlipak M, MacPhee S: Of Principles and Pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. Am J Med 2001; 110: 551–7. MEDLINE
11. Eckardt VF: Complimentary journeys to the World Congress of Gastroenterology – an inquiry of potential sponsors and beneficiaries. Z Gastroenterol 2000; 38: 7–11. MEDLINE
12. Coca V, Nink K, Schröder H: Arzneiverordnungen nach Arztgruppen. In: Schwabe U, Paffrath D (eds.): Arzneiverordnungsreport 2007. Berlin, Heidelberg, New York: Springer 2007; 905–18.
13. Orlowski JP, Wateska L: The effects of pharmaceutical firm enticements on physician prescribing patterns. There’s no such thing as a free lunch. Chest 1992; 102: 270–3. MEDLINE
14. Bowman MA, Pearle DL: Changes in drug prescribing patterns related to commercial company funding of continuing medical education. J Contin Educ Health Prof 1988; 8: 13–20. MEDLINE
15. Chren MM, Landefeld CS: Physicians’ behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA 1994; 271: 684–9. MEDLINE
16. Grande D, Frosch D, Perkins A, Kahn B: Effect of exposure to small pharmaceutical promotional items on treatment preferences. Arch Int Med 2009; 169: 887–93. MEDLINE
17. Watkins C, Harvey I, Carthy P, Moore L, Robinson E, Brawn R: Attitudes and behaviour of general practitioners and their prescribing costs: a national cross sectional survey. Qual Saf Health Care 2003; 12: 29–34. MEDLINE
18. van Schneider J, Arora V, Kasza K, Harrison R, Humphrey H: Residents’ perceptions over time of pharmaceutical industry interactions and gifts and the effect of an educational intervention. Acad Med 2006; 81: 595–602. MEDLINE
19. Randall ML, Rosenbaum JR: Attitudes and behaviors of psychiatry residents toward pharmaceutical representatives before and after an educational intervention. Acad Psychiatry 2005; 29: 33–9. MEDLINE
20. Mansfield PR, Lexchin J, Wen LS, et al.: Educating health professionals about drug and device promotion: advocates' recommendations. PLoS Med 2006; 3: 1988–91. MEDLINE
21. Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig WD, Lieb K: The financing of drug trials by pharmaceutical companies and its consequences: part1. A qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials [Finanzierung von Arzneimittelstudien durch pharmazeutische Unternehmen und die Folgen – Teil 1: Eine qualitative systematische Literaturübersicht zum Einfluss auf Studienergebnisse, -protokoll und -qualität]. Dtsch Arztebl Int 2010; 107(16): 279–85. VOLLTEXT
22. Schott G, Pachl H, Limbach U, Gundert-Remy U, Lieb K, Ludwig WD: The financing of drug trials by pharmaceutical companies and its consequences: part2. A qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication [Finanzierung von Arzneimittelstudien durch pharmazeutische Unternehmen und die Folgen – Teil 2: Eine qualitative systematische Literaturübersicht zum Einfluss auf Autorschaft, Zugang zu Studiendaten sowie auf Studienregistrierung und Publikation]. Dtsch Arztebl Int 2010; 107(17): 295–301. VOLLTEXT
23. Baethge C: Transparent texts [Transparente Texte]. Dtsch Arztebl Int 2008; 105(40): 675–9. VOLLTEXT